Needham Maintains ConMed(CNMD.US) With Buy Rating, Cuts Target Price to $61
Piper Sandler Maintains ConMed(CNMD.US) With Buy Rating, Maintains Target Price $80
Stifel Maintains ConMed(CNMD.US) With Hold Rating, Maintains Target Price $55
Conmed Price Target Cut to $58.00/Share From $70.00 by JP Morgan
Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $57
Conmed Is Maintained at Buy by Needham
Conmed Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Conmed (CNMD)
Conmed's Strong Q1 Performance and Raised Guidance Justify Buy Rating Despite Tariff Challenges
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Conmed (CNMD)
Stifel Maintains ConMed(CNMD.US) With Hold Rating, Maintains Target Price $55
CONMED Downgraded at Stifel on Airseal Disposable Purchasing Data, Tariffs
Conmed Analyst Ratings
Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75
Stifel Downgrades ConMed(CNMD.US) to Hold Rating, Cuts Target Price to $55
Conmed Is Maintained at Buy by Stifel
Needham Maintains ConMed(CNMD.US) With Buy Rating, Cuts Target Price to $91
Piper Sandler Maintains ConMed(CNMD.US) With Buy Rating, Maintains Target Price $80
Needham Maintains Buy on Conmed, Lowers Price Target to $91
Conmed Cut to Neutral From Overweight by JP Morgan